BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-389@pharmaconomics
DTSTAMP:20260707T033827Z
DTSTART;VALUE=DATE:20260504
DTEND;VALUE=DATE:20260505
SUMMARY:BBIO Approval — acoramidis
DESCRIPTION:A final FDA approval decision on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) is expected May 4\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000018/bbio-2026331xex991.htm\n\nTrack it: https://pharmaconomics.com/e/389
URL:https://pharmaconomics.com/e/389
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR